AR100859A1 - Polisacáridos y sus usos - Google Patents
Polisacáridos y sus usosInfo
- Publication number
- AR100859A1 AR100859A1 ARP150100534A ARP150100534A AR100859A1 AR 100859 A1 AR100859 A1 AR 100859A1 AR P150100534 A ARP150100534 A AR P150100534A AR P150100534 A ARP150100534 A AR P150100534A AR 100859 A1 AR100859 A1 AR 100859A1
- Authority
- AR
- Argentina
- Prior art keywords
- coli
- antigen
- protein
- detoxified
- carrier protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0066—Isolation or extraction of proteoglycans from organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una composición que comprende un bioconjugado de un antígeno O25B de E. coli acoplado covalentemente con una proteína portadora, en donde el antígeno O25B de E. coli comprende la estructura de la fórmula (1), en donde n es un número entero de entre 1 y 30. Reivindicación 11: Un método para inducir la producción de anticuerpos opsonofagocíticos en un sujeto que son específicos de Escherichia coli patogénico extraintestinal, que comprende la administración al sujeto de una cantidad efectiva de la composición de acuerdo con cualquiera de las reivindicaciones 1 - 8. Reivindicación 18: La célula huésped de acuerdo con la reivindicación 16 ó 17, en donde la proteína portadora se selecciona del grupo que consiste en Exotoxina A detoxificada de P. aeruginosa (EPA), CRM197, proteína de unión a maltosa (MBP), toxoide de difteria, toxoide tetánico, hemolisina A detoxificado de S. aureus, factor de aglutinación A, factor de aglutinación B, FimH de E. coli, FimHC de E. coli, enterotoxina lábil al calor de E. coli, variantes detoxificadas de enterotoxina lábil al calor de E. coli, subunidad de toxina B del cólera (CTB), toxina del cólera, variantes detoxificadas de toxina del cólera, proteína Sat de E. coli, el dominio pasajero de proteína Sat de E. coli, neumolisina de Streptococcus pneumoniae y sus variantes detoxificadas, AcrA de C. jejuni y glicoproteínas naturales de C. jejuni. Reivindicación 20: Un método de preparación de una proteína portadora N-glicosilada que comprende un antígeno O25B de E. coli, que comprende: a) cultivar la célula huésped de acuerdo con cualquiera de las reivindicaciones 16 - 19; y b) purificar una proteína portadora N-glicosilada que comprende antígeno O25B de E. coli.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461943710P | 2014-02-24 | 2014-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR100859A1 true AR100859A1 (es) | 2016-11-09 |
Family
ID=52589386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP150100534A AR100859A1 (es) | 2014-02-24 | 2015-02-23 | Polisacáridos y sus usos |
Country Status (21)
Country | Link |
---|---|
US (5) | US9700612B2 (es) |
EP (1) | EP3110441B1 (es) |
JP (2) | JP6276427B2 (es) |
KR (1) | KR101855142B1 (es) |
CN (1) | CN106535927B (es) |
AR (1) | AR100859A1 (es) |
AU (1) | AU2015220723C1 (es) |
CA (1) | CA2940547C (es) |
CL (1) | CL2016002123A1 (es) |
DK (1) | DK3110441T3 (es) |
EA (1) | EA035991B9 (es) |
FI (1) | FI3110441T3 (es) |
IL (1) | IL247344B (es) |
LT (1) | LT3110441T (es) |
MX (1) | MX2016011055A (es) |
NZ (1) | NZ723328A (es) |
PH (1) | PH12016501671B1 (es) |
PT (1) | PT3110441T (es) |
SG (1) | SG11201606889PA (es) |
TW (1) | TWI639439B (es) |
WO (1) | WO2015124769A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9849169B2 (en) | 2013-01-17 | 2017-12-26 | Arsanis Biosciences Gmbh | MDR E. coli specific antibody |
SG11201606889PA (en) | 2014-02-24 | 2016-09-29 | Glycovaxyn Ag | Novel polysaccharide and uses thereof |
JP2018515517A (ja) * | 2015-05-13 | 2018-06-14 | ユニバーシティ オブ ワシントンUniversity of Washington | 尿路病原性大腸菌感染病の処置と予防のための組成物および方法 |
TWI715617B (zh) * | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
AR109621A1 (es) * | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
GB201711637D0 (en) * | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
WO2019175147A1 (en) | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccines against intra-abdominal infections |
CN108531439B (zh) * | 2018-04-16 | 2020-04-07 | 南京工业大学 | 一种大肠杆菌基因工程菌及其构建方法与应用 |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CA3134045A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
PE20212265A1 (es) | 2019-03-18 | 2021-11-30 | Janssen Pharmaceuticals Inc | Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos |
CN110018253A (zh) * | 2019-04-15 | 2019-07-16 | 艾美卫信生物药业(浙江)有限公司 | 一种生物制品中游离蛋白含量的高效液相测定方法 |
CN111855826B (zh) * | 2019-04-24 | 2022-09-16 | 岛津企业管理(中国)有限公司 | 破伤风类毒素或白喉类毒素的监测方法 |
GB201908528D0 (en) * | 2019-06-13 | 2019-07-31 | Univ Dundee | Rhamnose-polysaccharides |
JP7485771B2 (ja) | 2020-01-16 | 2024-05-16 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | FimH変異体、その組成物、及びその使用 |
WO2021255684A1 (en) | 2020-06-18 | 2021-12-23 | Glaxosmithkline Biologicals Sa | Shigella-tetravalent (shigella4v) bioconjugate |
CN116209753A (zh) | 2020-06-25 | 2023-06-02 | 葛兰素史克生物有限公司 | 肺炎克雷伯氏菌o-抗原疫苗 |
WO2022058945A1 (en) | 2020-09-17 | 2022-03-24 | Janssen Pharmaceuticals, Inc. | Multivalent vaccine compositions and uses thereof |
US20230349913A1 (en) * | 2020-11-30 | 2023-11-02 | Janssen Pharmaceuticals, Inc. | Analytical method for glycogonjugates using a capillary-based immunoassay system |
US11725028B2 (en) | 2021-01-12 | 2023-08-15 | Janssen Pharmaceuticals, Inc. | FimH mutants, compositions therewith and use thereof |
WO2022178020A1 (en) | 2021-02-16 | 2022-08-25 | Duke University | Vaccine compositions and methods for the treatment and prevention of urinary tract infections |
US20220323576A1 (en) | 2021-04-01 | 2022-10-13 | Janssen Pharmaceuticals, Inc. | Production of E. coli O18 Bioconjugates |
WO2022214620A1 (en) | 2021-04-08 | 2022-10-13 | Janssen Pharmaceuticals, Inc. | Process for bioconjugate production |
WO2023118033A1 (en) | 2021-12-22 | 2023-06-29 | Glaxosmithkline Biologicals Sa | Vaccine |
CN114150005B (zh) * | 2022-02-09 | 2022-04-22 | 广州恩宝生物医药科技有限公司 | 用于预防SARS-CoV-2奥密克戎株的腺病毒载体疫苗 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3700612A (en) | 1971-06-23 | 1972-10-24 | Tenneco Chem | Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5370872A (en) | 1991-08-12 | 1994-12-06 | Swiss Serum And Vaccine Institute Berne | Escherichia coliO-polysaccharide-protein conjugate vaccine |
WO2003074687A1 (en) | 2002-03-07 | 2003-09-12 | Eidgenössische Technische Hochschule Zürich | System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
CN101360831B (zh) | 2005-05-11 | 2013-07-10 | Eth苏黎世公司 | 来自原核细胞的重组n-糖基化蛋白 |
EP2010537B1 (en) | 2006-03-23 | 2011-12-28 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
CA2711503A1 (en) | 2008-01-08 | 2009-07-16 | Biogenerix Ag | Glycoconjugation of polypeptides using oligosaccharyltransferases |
JP5782258B2 (ja) * | 2008-02-20 | 2015-09-24 | グリコヴァキシン アーゲー | 原核細胞由来の組換えn−グリコシル化タンパク質から作製したバイオコンジュゲート |
CA2780487C (en) | 2009-11-19 | 2019-05-21 | Glycovaxyn Ag | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
CN103391714A (zh) | 2010-12-10 | 2013-11-13 | 默沙东公司 | 减轻搅动引起的免疫原性组合物聚集的新制剂 |
WO2013034664A1 (en) | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
US9932598B2 (en) | 2012-08-02 | 2018-04-03 | The Regents Of The University Of California | Metabolic engineering of microbial organisms |
CA2883000A1 (en) | 2012-09-10 | 2014-03-13 | Glycovaxyn Ag | Bioconjugates comprising modified antigens and uses thereof |
US20150267207A1 (en) | 2012-10-12 | 2015-09-24 | Glycovaxyn Ag | Methods of host cell modification |
JP2016501550A (ja) | 2012-12-27 | 2016-01-21 | グリコヴァキシン アーゲー | Crm197に関する方法及び組成物 |
US9849169B2 (en) * | 2013-01-17 | 2017-12-26 | Arsanis Biosciences Gmbh | MDR E. coli specific antibody |
SG11201602546RA (en) | 2013-10-11 | 2016-04-28 | Glycovaxyn Ag | Methods of host cell modification |
US20170145079A1 (en) | 2014-02-06 | 2017-05-25 | Arsanis Biosciences Gmbh | E. coli specific antibody sequences |
SG11201606889PA (en) * | 2014-02-24 | 2016-09-29 | Glycovaxyn Ag | Novel polysaccharide and uses thereof |
ES2907211T3 (es) | 2014-12-30 | 2022-04-22 | Glaxosmithkline Biologicals Sa | Composiciones y métodos para la glicosilación de proteínas |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
AR109621A1 (es) | 2016-10-24 | 2018-12-26 | Janssen Pharmaceuticals Inc | Formulaciones de vacunas contra glucoconjugados de expec |
GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
CA3134045A1 (en) | 2019-03-18 | 2020-09-24 | Janssen Pharmaceuticals, Inc. | Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof |
PE20212265A1 (es) | 2019-03-18 | 2021-11-30 | Janssen Pharmaceuticals Inc | Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos |
-
2015
- 2015-02-23 SG SG11201606889PA patent/SG11201606889PA/en unknown
- 2015-02-23 WO PCT/EP2015/053739 patent/WO2015124769A1/en active Application Filing
- 2015-02-23 CA CA2940547A patent/CA2940547C/en active Active
- 2015-02-23 CN CN201580020077.8A patent/CN106535927B/zh active Active
- 2015-02-23 NZ NZ723328A patent/NZ723328A/en unknown
- 2015-02-23 FI FIEP15706459.3T patent/FI3110441T3/fi active
- 2015-02-23 AR ARP150100534A patent/AR100859A1/es unknown
- 2015-02-23 MX MX2016011055A patent/MX2016011055A/es unknown
- 2015-02-23 JP JP2016570184A patent/JP6276427B2/ja active Active
- 2015-02-23 KR KR1020167026424A patent/KR101855142B1/ko active IP Right Grant
- 2015-02-23 LT LTEPPCT/EP2015/053739T patent/LT3110441T/lt unknown
- 2015-02-23 EA EA201691478A patent/EA035991B9/ru unknown
- 2015-02-23 DK DK15706459.3T patent/DK3110441T3/da active
- 2015-02-23 US US14/628,844 patent/US9700612B2/en active Active
- 2015-02-23 EP EP15706459.3A patent/EP3110441B1/en active Active
- 2015-02-23 PT PT157064593T patent/PT3110441T/pt unknown
- 2015-02-23 AU AU2015220723A patent/AU2015220723C1/en active Active
- 2015-02-24 TW TW104105953A patent/TWI639439B/zh active
-
2016
- 2016-08-18 IL IL247344A patent/IL247344B/en active IP Right Grant
- 2016-08-23 CL CL2016002123A patent/CL2016002123A1/es unknown
- 2016-08-23 PH PH12016501671A patent/PH12016501671B1/en unknown
-
2017
- 2017-07-07 US US15/643,788 patent/US10441647B2/en active Active
-
2018
- 2018-01-11 JP JP2018002276A patent/JP6771499B2/ja active Active
-
2019
- 2019-10-11 US US16/599,900 patent/US10940192B2/en active Active
-
2021
- 2021-02-02 US US17/165,333 patent/US11738076B2/en active Active
-
2023
- 2023-04-24 US US18/305,948 patent/US20230364214A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR100859A1 (es) | Polisacáridos y sus usos | |
BR112018003469A2 (pt) | composição, método para induzir uma resposta imune a e. coli patogênica extraintestinal, e, processo para produzir uma composição. | |
PH12021550318A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
MX2022014850A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
MX2022009927A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
MX2022009928A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
PH12018500037A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof | |
MX2020002555A (es) | Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. | |
BR112018007812A2 (pt) | polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica. | |
MX371453B (es) | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. | |
AR092897A1 (es) | Composiciones inmunogenicas | |
PH12019500561A1 (en) | Expec glycoconjugate vaccine formulations | |
MX2016000099A (es) | Vacunas sinteticas contra streptococcus pneumoniae tipo 1. | |
PH12018501205A1 (en) | Synthetic vaccines against streptococcus pneumoniae serotype 2 | |
AR105793A1 (es) | Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal | |
AR114693A1 (es) | Vacunas contra infecciones intraabdominales | |
PL408955A1 (pl) | Immunogenny koniugat i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez pałeczki jelitowe z rodziny Enterobacteriaceae |